Not Signed In -
Diclofenac Potassium |
Cataflam |
Clinical Trial: A Study to Evaluate the Renal Protective Effects of Losartan in Patients with Renal Transplant.
This study is no longer recruiting patients.
|
Purpose
A study to determine the renal protective effect (measured as an incidence of chronic allograft nephropathy)of losartan in patients after renal transplant.
| Condition | Intervention | Phase |
|---|---|---|
| Renal Disorder | Drug: MK0954, losartan potassium | Phase IV |
MedlinePlus related topics: Kidney Diseases
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study
Official Title: Extension Study Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Renal Protective Effects of Losartan in Patients with Renal Transplants
Further Study Details:
Study start: April 2000
Eligibility
Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
- Males or females at least 18 years of age who have undergone a renal transplant.
Location Information
Spain
Merck Sharp & Dohme De Espana, S.A.E., Madrid, 28027, Spain
Study chairs or principal investigators
Medical Monitor, Study Director, Merck
More Information
Study ID Numbers: 2005_053
Last Updated: August 31, 2005
Record first received: August 30, 2005
ClinicalTrials.gov Identifier: NCT00140907
Health Authority: Spain: Ministry of Health
ClinicalTrials.gov processed this record on 2005-09-13
Last Updated: August 31, 2005
Record first received: August 30, 2005
ClinicalTrials.gov Identifier: NCT00140907
Health Authority: Spain: Ministry of Health
ClinicalTrials.gov processed this record on 2005-09-13
Resources
- Cataflam (Drug Digest)
- Diclofenac Potassium (Drug Digest)
email this page
print this page
bookmark this page
feedback on this page
